Ramona Trebbien

Ramona Trebbien

Auto-generated profile, based on publicly available information

Ramona Trebbien

Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet
Verified
Journal Article
Closed access
AIA Danielle Iuliano
A Danielle Iuliano
KRKatherine M Roguski
Katherine M Roguski
HCHoward H Chang
Howard H Chang
DMDavid J Muscatello
David J Muscatello
RPRakhee Palekar
Rakhee Palekar
DMDesiree Mustaquim
Desiree Mustaquim

1 March 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
HBHenning Bundgaard
Henning Bundgaard
JBJohan Bundgaard
Johan Bundgaard
DRDaniel Emil Tadeusz Raaschou-Pedersen
Daniel Emil Tadeusz Raaschou-Pedersen
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
Tobias TodsenTobias Todsen
Tobias Todsen
KIKasper Iversen
Kasper Iversen
Observational evidence suggests that mask wearing mitigates SARS-CoV-2 transmission. It is uncertain if this observed association arises through protection of uninfected wearers (protective effect)... Visual Effectiveness of Mask Recommendation for Preventing SARS-CoV-2 Infection Observational evidence suggests that mask wearing mitigates SARS-CoV-2 transmission. It is uncertain if this... Background: Observational evidence suggests that mask wearing mitigates transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is uncertain if this observed association ar...

8 September 2011 in Virology Journal
Verified
Journal Article
Open access
PDF file
RTRamona Trebbien
Ramona Trebbien
LLlars Larsen
lars Larsen
BVBirgitte M Viuff
Birgitte M Viuff
Pigs are considered susceptible to influenza A virus infections from different host origins because earlier studies have shown that they have receptors for both avian (sialic acid-alpha-2,3-terminal saccharides (SA-alpha-2,3)) and swine/human (SA-alpha-2,6) influenza viruses in the upper respiratory tract. Furthermore, experimental and natural infections in pigs have been reported with influenza A virus from avian and human sources.

1 October 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
JNJ. Nielsen
J. Nielsen
LVL.S. Vestergaard
L.S. Vestergaard
LRL. Richter
L. Richter
DSD. Schmid
D. Schmid
NBN. Bustos
N. Bustos
TKT.G. Krause
T.G. Krause
Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high excess mortality during the influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe all-cause excess and influenza-attributable mortality during the season 2017/18 in Europe. Based on weekly reporting of mortality from 24 European countries or sub-national regions, representing 60% of the European population excluding the Russian and Turkish parts of Europe, we estimated age stratified all-cause excess morality using the EuroMOMO model. In addition, age stratified all-cause influenza-attributable mortality was estimated using the FluMOMO algorithm, incorporating influenza activity based on clinical and virological surveillance data, and adjusting for extreme temperatures. Excess mortality was mainly attributable to influenza activity from December 2017 to April 2018, but also due to exceptionally low temperatures in February-March 2018. The pattern and extent of mortality excess was similar to the previous A(H3N2) dominated seasons, 2014/15 and 2016/17. The 2017/18 overall all-cause influenza-attributable mortality was estimated to be 25.4 (95%CI 25.0-25.8) per 100,000 population; 118.2 (116.4-119.9) for persons aged 65. Extending to the European population this translates into over-all 152,000 deaths. The high mortality among elderly was unexpected in an influenza B dominated season, which commonly are considered to cause mild illness, mainly among children. Even though A(H3N2) also circulated in the 2017/18 season and may have contributed to the excess mortality among the elderly, the common perception of influenza B only having a modest impact on excess mortality in the older population may need to be reconsidered.

1 March 2018 in Eurosurveillance
Verified
Journal Article
Open access
MRMarc Rondy
Marc Rondy
EKEsther Kissling
Esther Kissling
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
AGAlin Gherasim
Alin Gherasim
RPRichard Pebody
Richard Pebody
VVVesna Višekruna Vučina
Vesna Višekruna Vučina
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

1 September 2024 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
CKCharlotte Kristensen
Charlotte Kristensen
HJHenrik Elvang Elvang Jensen
Henrik Elvang Elvang Jensen
RTRamona Trebbien
Ramona Trebbien
RWRichard J. Webby
Richard J. Webby
LLlars Larsen
lars Larsen
Influenza Virus Receptors in Bovine Mammary Gland